Overview

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Antibodies, Monoclonal